These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 34078259

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study.
    Ahmed F, Gaul C, García-Moncó JC, Sommer K, Martelletti P, REPOSE Principal Investigators.
    J Headache Pain; 2019 Mar 07; 20(1):26. PubMed ID: 30845917
    [Abstract] [Full Text] [Related]

  • 3. Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data.
    Davies B, Gaul C, Martelletti P, García-Moncó JC, Brown S.
    J Headache Pain; 2017 Sep 06; 18(1):93. PubMed ID: 28879545
    [Abstract] [Full Text] [Related]

  • 4. OnabotulinumtoxinA Reduces Health Resource Utilization in Chronic Migraine: PREDICT Study.
    Becker WJ, Boudreau G, Finkelstein I, Graboski C, Ong M, Christie S, Sommer K, Bhogal M, Davidovic G.
    Can J Neurol Sci; 2023 May 06; 50(3):418-427. PubMed ID: 35466897
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States.
    Tepper SJ, Fang J, Zhou L, Shen Y, Vo P, Abdrabboh A, Glassberg MB, Ferraris M.
    J Manag Care Spec Pharm; 2021 Sep 06; 27(9):1157-1170. PubMed ID: 33998825
    [Abstract] [Full Text] [Related]

  • 7. Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe.
    Matharu M, Pascual J, Nilsson Remahl I, Straube A, Lum A, Davar G, Odom D, Bennett L, Proctor C, Gutierrez L, Andrews E, Johannes C.
    Cephalalgia; 2017 Dec 06; 37(14):1384-1397. PubMed ID: 28758415
    [Abstract] [Full Text] [Related]

  • 8. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK, Sadowsky CH, Martinez WC, Zuniga JA, Poulette A.
    Headache; 2012 Sep 06; 52(8):1219-25. PubMed ID: 22607530
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting.
    Santoro A, Fontana A, Miscio AM, Zarrelli MM, Copetti M, Leone MA.
    Neurol Sci; 2017 Oct 06; 38(10):1779-1789. PubMed ID: 28726049
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience.
    Negro A, Curto M, Lionetto L, Martelletti P.
    J Headache Pain; 2015 Oct 06; 17():1. PubMed ID: 26792662
    [Abstract] [Full Text] [Related]

  • 19. Real-world effectiveness of onabotulinumtoxinA treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study.
    Stark C, Stark R, Limberg N, Rodrigues J, Cordato D, Schwartz R, Jukic R.
    J Headache Pain; 2019 Jul 15; 20(1):81. PubMed ID: 31307383
    [Abstract] [Full Text] [Related]

  • 20. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
    Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT Chronic Migraine Study Group.
    Headache; 2010 Jun 15; 50(6):921-36. PubMed ID: 20487038
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.